Lantheus Stock (NASDAQ:LNTH)
Previous Close
$79.43
52W Range
$50.20 - $126.89
50D Avg
$104.47
200D Avg
$85.88
Market Cap
$6.01B
Avg Vol (3M)
$881.20K
Beta
0.51
Div Yield
-
LNTH Company Profile
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
LNTH Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
Product/Service | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
PYLARIFY | $851.30M | $527.40M | $43.41M |
Product | $1.26B | - | - |
Total Precision Diagnostics | $390.12M | $356.68M | $351.02M |
Techne Lite | $87.37M | $88.86M | $91.29M |
Other Precision Diagnostics | $22.98M | $22.82M | $26.97M |
License and Royalty Revenues | $33.36M | $48.02M | $24.85M |
DEFINITY | $279.77M | $244.99M | $232.76M |
Radiopharmaceutical Oncology | $854.43M | $531.51M | $48.89M |
Strategic Partnerships And Other | $51.88M | $46.87M | $25.30M |
Other Radiopharmaceutical Oncology | $3.13M | $4.10M | $5.47M |
Product Revenue, Net | - | $887.04M | $400.36M |
Peer Comparison
Ticker | Company |
---|---|
RDY | Dr. Reddy's Laboratories Limited |
ANIP | ANI Pharmaceuticals, Inc. |
AQST | Aquestive Therapeutics, Inc. |
DVAX | Dynavax Technologies Corporation |
NBIX | Neurocrine Biosciences, Inc. |
IRWD | Ironwood Pharmaceuticals, Inc. |
DERM | Journey Medical Corporation |
DCPH | Deciphera Pharmaceuticals, Inc. |
ALKS | Alkermes plc |
PCRX | Pacira BioSciences, Inc. |
COLL | Collegium Pharmaceutical, Inc. |
CTLT | Catalent, Inc. |
AVDL | Avadel Pharmaceuticals plc |
AMPH | Amphastar Pharmaceuticals, Inc. |